AGÕæÈ˹ٷ½

STOCK TITAN
  1. Home
  2. Sec-filings
  3. ALLO
  4. [SCHEDULE 13G] Allogene Therapeutics, Inc. SEC Filing

[SCHEDULE 13G] Allogene Therapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source:

Stock ALLO logo
Allogene Therapeutics

NASDAQ:ALLO

ALLO Rankings

#4759 Ranked by Market Cap
N/A Ranked by Dividends

ALLO Latest News

Aug 1, 2025
Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma
Jun 1, 2025
Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO
May 23, 2025
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
May 22, 2025
Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel
May 13, 2025
Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update

ALLO Latest SEC Filings

Aug 1, 2025
[8-K] Allogene Therapeutics, Inc. Reports Material Event
Jun 23, 2025
[Form 4] Allogene Therapeutics, Inc. Insider Trading Activity
Jun 23, 2025
[Form 4] Allogene Therapeutics, Inc. Insider Trading Activity
Jun 23, 2025
[Form 4] Allogene Therapeutics, Inc. Insider Trading Activity
Jun 23, 2025
[Form 4] Allogene Therapeutics, Inc. Insider Trading Activity

ALLO Stock Data

282.16M
148.74M
17.73%
77.84%
18.65%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
SOUTH SAN FRANCISCO